Baicalein Anti-Tumor Effects on Choroidal Melanoma via PI3K/AKT/mTOR Pathway

Table 4 contains integrated analysis data from a study investigating the flavonoid baicalein's effects on choroidal melanoma. Lili Wu authored this 12.8 KB Excel file, which was last updated in April 2026. The data supports findings that baicalein inhibits tumor progression by modulating the PI3K/AKT/mTOR signaling pathway.

Use Cases

• Identify potential drug targets for choroidal melanoma by analyzing network pharmacology and molecular docking results.
• Validate transcriptomic analysis findings linking baicalein treatment to cell cycle, apoptosis, and PI3K/AKT/mTOR pathway modulation.
• Correlate in vitro experimental results, such as proliferation inhibition and cell cycle arrest, with predicted signaling pathway activity.
• Assess the dependency of baicalein's effects on the PI3K/AKT/mTOR axis using data from IGF-1 co-treatment experiments.

Strengths

• Data integrates three methodologies: network pharmacology, transcriptomics, and experimental validation.
• Findings are supported by in vitro experiments on two cell lines (C918 and OCM-1) and an allograft tumor model.
• File is openly licensed under CC-BY-4.0 for reuse.

Limitations

• The dataset is very small at 12.8 KB, indicating limited scope and likely a single summary table.
• Specific row counts, column names, and sample data are unavailable, limiting detailed analysis.
• Data is derived from a single study, so findings are not independently replicated.

Provenance

Source

Lili Wu, via the figshare repository.

Collection Method

Generated through integrated network pharmacology, transcriptomic analysis, molecular docking, and in vitro/in vivo experimental validation.

Time Range

null

Freshness

Last updated in April 2026.

Geography

null